Update as of 25 May 2022:
On 24 May 2022, the European Commission issued a legal decision confirming the suspension of the marketing authorisations of HES solutions for infusion.
If necessary for public health reasons, individual EU Member States may delay the suspension for no longer than 18 months and keep HES solutions on the market, subject to agreed risk minimisation measures….
